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Abstract
Alpha1-antitrypsin deficiency is an autosomal reces-
sive disease characterized by reduced serum levels of 
alpha1-antitrypsin (AAT) due to mutations in the SER-
PINA1  gene causing early onset pulmonary emphyse-
ma and, occasionally, chronic liver disease. We report 
an incidental finding of a novel null AAT allele, Q0Milano, 
consisting of a 17 nucleotides deletion in exon 3 of 
SERPINA1  gene, in an Italian child with persistently 
increased liver enzymes, a mild decrease in circulating 
AAT levels and without any pulmonary disease. Q0Milano 
variant results in an unfunctional protein lacking of AAT 
active site, as the resultant protein is truncated near 
PiS locus involved in AAT protein stability.
© 2013 Baishideng. All rights reserved.
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Core tip: We report an incidental finding of a novel null 
alpha1-antitrypsin (AAT) allele, Q0Milano, consisting of a 
17 nucleotides deletion in exon 3 of SERPINA1  gene, 
in an Italian child with persistently increased in liver 
enzymes and a mild decrease in circulating AAT levels. 
Q0Milano variant results in an unfunctional protein lack-
ing of AAT active site, as the resultant protein is trun-
cated near PiS locus involved in AAT protein stability.
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INTRODUCTION
Alpha1-antitrypsin deficiency (AATD) is an autosomal 
recessive disease characterized by reduced serum levels 
of  alpha1-antitrypsin (AAT, SERPINA1), a 52 kDa gly-
coprotein functioning as the main extracellular protease 
inhibitor. AAT is mainly produced by liver, which releases 
about 2 g of  AAT daily into the circulation under physio-
logical conditions. The normal serum concentration may 
range between 1.5-3.5 g/L (or 20-48 μmol/L)[1]. AATD 
is associated with early onset pulmonary emphysema and, 
occasionally, with chronic liver disease in childhood, he-
patocellular carcinoma and/or cirrhosis in adulthood[2]. 
AAT functions as neutrophil elastase inhibitor, playing a 
key role in the protection of  the lower respiratory tract. 
AAT serum levels below 11 μmol/L are not sufficient to 
inhibit elastase in vivo, permitting progressive destruction 
of  alveoli culminating in emphysema[3-5]. The pathophysi-
ology of  liver disease related to AATD is less well un-
derstood, but some deficient variants accumulate in en-
doplasmic reticulum of  hepatocytes and are inefficiently 
secreted, leading to protein aggregation and culminating 
in hepatocytes injury and liver disease[6]. 
AATD is caused by mutations in SERPINA1, a 
highly polymorphic genetic locus located on the distal 
long arm of  chromosome 14. More than 100 alleles have 
been identified. They can be classified according to AAT 
serum levels and protein functionality: (1) normal vari-
ants, all common M types, accounting for 95% of  those 
found in Caucasian individuals, and characterized by nor-
mal plasma levels (more than 20 μmol/L); (2) deficient 
variants associated with reduced AAT serum levels, lower 
than 20 μmol/L; (3) null variants determining undetect-
able serum levels; and (4) dysfunctional variants charac-
terized by normal serum levels of  dysfunctional AAT 
protein[7].
The firstly described, and most common cause of  
AATD, associated with very low serum concentration of  
the protein, is homozygosity for the PiZ mutation, the 
most severe AAT deficient variant known with plasma 
levels among homozygotes of  about 5-6 μmol/L, result-
ing in the development of  lung and liver disease[8]. It 
became later clear that AATD is a heterogeneous disease, 
caused by several gene defects expressed codominantly, 
mostly determining reduced serum AAT levels. 
The most common deficient alleles are PiS and PiZ, 
with an allelic frequency of  2%-4% and 1%-2% respec-
tively in Caucasian population, and are both caused by 
missense mutations responsible for intracellular protein 
accumulation and degradation. The PiZ mutation leads 
to a conformational change of  AAT reactive site into a 
β-sheet polymer which forms characteristic periodic acid-
Schiff-positive inclusions and can be isolated for liver 
of  AAT PiZZ subjects. Several studies have shown that 
PiMZ in heterozygous state may lead to chronic liver 
disease, cryptogenic cirrhosis, and chronic active hepati-
tis[9-11], while the PiS variant is associated to liver disease 
only if  carried in compound heterozygosity with the PiZ 
allele[12]. Null alleles are very rare (frequency < 0.001, 
13% of  AATD subjects in Italy[13]) and derived from nu-
cleotide deletion, insertion, or non-sense mutations, caus-
ing premature stop codons and producing structurally 
unstable and truncated protein. Individuals with null-null 
AAT phenotype are not affected by liver disease, because 
of  the lack of  aggregation of  mutant proteins in the en-
doplasmic reticulum, but are associated with an increased 
risk of  emphysema.
In this study we report a novel AAT allele in a child 
with reduced protein levels.
CASE REPORT
An 11-years-old male child was referred to our centre for 
a persistent increase in liver enzymes (aspartate amino-
transferase and alanine aminotransferase spanning from 
58-239 UI/L, and 98-114 UI/L respectively). All com-
mon causes of  liver disease were excluded, but mildly 
decreased AAT serum levels were detected (76 mg/dL). 
The subject did not show abnormalities in pulmonary 
function.
Sequencing of  the proband revealed a novel null 
mutation in AAT gene (Table 1), g.9752-9768del (PiQ0Mi-
lano) (gene ID: 5265, official name SERPINA1, genomic 
sequence number: NC_000014.8; NCBI Reference Se-
quence: NG_008290.1). This variant, localized in exon 3 
near PiS locus (p.Glu264Val), consists in a 17 bp deletion 
(AAA CTA CAG CAC CTG GA), resulting in a frame-
shift causing a new stop codon downstream the deletion 
site (Figure 1), which leads to a premature termination of  
protein translation at amino acid 259. The truncated pro-
tein lacks of  AAT active site centred around Met358-Ser359. 
The mutation arose in PiM3 AAT allele, which the 
proband inherited from his mother, whose genotype was 
PiM1A/Q0Milano and had normal liver and pulmonary 
function, whereas his father, who had normal genotype 
PiM1V/PiM3, showed nonalcoholic steatohepatitis as-
sociated with hyperferritinemia (Figure 2). Liver biopsy 
of  the proband showed aspecific findings, unrelated to 
AATD.
DISCUSSION
The g.9752-9768del mutation (Q0Milano) occurs in a key 
functional region of  AAT gene where several other de-
ficiency variants (PLowell/PDuarte at codon 256, Q0Cairo at 
codon 259, T/S at codon 264) have been reported[14-18].
Several mechanisms are responsible for AAT defi-
ciency, including: gene deletion, mRNA degradation, 
intracellular protein accumulation and degradation, and 
production of  dysfunctional proteins. Only mutations 
causing intracellular protein accumulation and polymer-
ization of  the newly synthesized protein are associated 
with increased risk of  liver disease, as in PiZ and in PiM-
Malton variants[19]. Many previously described null muta-
tions (PiDuarte, PiHong Kong, PiGranite Falls) have been associated 
with intra-reticular accumulation of  unfunctional AAT 
proteins, which are immediately degraded without any 
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Table 1  Sequence of primers used in Alpha1-antitrypsin coding sequence 
amplification and sequencing
Primers forward 5’→3’ Primers reverse 5’→3’
AAT Ex2A CCCCCCATCTCTGTCTTGC GAGGAGTTCCTGGAAGCCTT
AAT Ex2B ATGAAATCCTGGAGGGCCTG CAGGCTGGTTGAGCAACCTT
AAT Ex3 CCCACCTTCCCCTCTCTCC CACCCTCAGGTTGGGGAATC
AAT Ex4 CTTGAATTTCTTTTCTGCACGAC AAGGTCGTCAGGGTGATCTC
AAT Ex5 GTCTCTGCTTCTCTCCCCTC AGGGACCAGCTCAACCCTTC
AAT: Alpha1-antitrypsin; Ex: Exon.
liver damage[20-22]. Heterozygosity for this novel null mu-
tation is consistent with the lower AAT serum levels (76 
mg/dL) measured in the proband, which collocates the 
patient in intermediate deficiency condition comparable 
to those of  individuals carrying PiMZ genotype[23]. 
However, it is unlikely that this genetic variant ex-
plained liver disease in the proband, as it was carried in 
heterozygous state, and it does not affected liver function 
tests of  the mother. Moreover, the absence of  periodic 
acid-Schiff-positive inclusions revealed in liver biopsy 
excluded hepatic AAT protein accumulation. Thus, the 
novel null AAT variant was not responsible for liver 
damage because of  the lack of  hepatic protein polymer-
ization.
It is likely that other hepatotoxic insults, as non alco-
holic steatohepatitis associated with hyperferritinemia, 
a strongly heritable condition reported in the father of  
proband[24,25], were involved in the development of  liver 
disease. 
In conclusion, in this study we report a novel AAT 
null variant (Q0Milano) generated by a 17 nucleotides dele-
tion in exon 3 of  AAT, which leads to a premature stop 
codon.
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Figure 1  Schematic representation of wild type and mutant Alpha1-anti-
trypsin gene and protein. A: Alpha1-antitrypsin (AAT) wild type gene; B: AAT 
mutated gene: Bule region represents out of frame sequence. Untranslated re-
gions are shown in black; C: AAT wild type protein: Exon 3 wild-type sequence 
is indicated in square; the deleted nucleotides are underlined; PiS locus is 
highlighted; D: AAT truncated unfunctional protein; Exon 3 deleted sequence is 
indicated below; premature stops codons resulting from frameshift were under-
lined.
M1V/M3 M1A/Q0Milano
M1V/Q0Milano
Figure 2  Pedigree of the Q0Milano proband’s family. Alpha1-antitrypsin geno-
types are listed below.
EX Ⅱ EX Ⅲ EX Ⅳ EX Ⅴ
192 ggc aaa tgg gag aga ccc ttt gaa gtc aag gac acc aga gaa gag
207 gac ttc cac gtg gac cag gtg acc acc gtg aag gtg cct atg atg
222 aag cgt tta ggc atg ttt aac atc cag cac tgt aag aag ctg tcc
237 agc tgg gtg ctg ctg atg aaa tac ctg ggc aat gcc acc gcc atc
252 ttc ttc ctg cct gat gag ggg AAA CTA CAG CAC CTG GAa aat gaa
267 ctc acc cac gat atc atc acc aag ttc ctg gaa aat gaa gac aga
C
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